Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting

In the field of nasal drug delivery, nose-to-brain delivery is among the most fascinating applications, directly targeting the central nervous system, bypassing the blood brain barrier. Its benefits include dose lowering and direct brain distribution of potent drugs, ultimately reducing systemic sid...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2018-03, Vol.10 (1), p.34
Main Authors: Sonvico, Fabio, Clementino, Adryana, Buttini, Francesca, Colombo, Gaia, Pescina, Silvia, Stanisçuaski Guterres, Silvia, Raffin Pohlmann, Adriana, Nicoli, Sara
Format: Article
Language:English
Subjects:
Alzheimer’s disease
CNS disorders
mucoadhesion
mucus-penetrating particles
nanoparticles
neurodegenerative diseases
nose-to-brain delivery
Parkinson’s disease
pharmaceutical nanotechnology
Review
targeting
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In the field of nasal drug delivery, nose-to-brain delivery is among the most fascinating applications, directly targeting the central nervous system, bypassing the blood brain barrier. Its benefits include dose lowering and direct brain distribution of potent drugs, ultimately reducing systemic side effects. Recently, nasal administration of insulin showed promising results in clinical trials for the treatment of Alzheimer's disease. Nanomedicines could further contribute to making nose-to-brain delivery a reality. While not disregarding the need for devices enabling a formulation deposition in the nose's upper part, surface modification of nanomedicines appears the key strategy to optimize drug delivery from the nasal cavity to the brain. In this review, nanomedicine delivery based on particle engineering exploiting surface electrostatic charges, mucoadhesive polymers, or chemical moieties targeting the nasal epithelium will be discussed and critically evaluated in relation to nose-to-brain delivery.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics10010034